Article Text

PDF
New therapies for inflammatory bowel disease: from the bench to the bedside
  1. Silvio Danese
  1. Correspondence to Dr Silvio Danese, IBD Center, Division of Gastroenterology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy; sdanese{at}hotmail.com

Abstract

The mechanisms underlying the chronic intestinal inflammation that is a hallmark of inflammatory bowel diseases (IBD) are complex. Components of the pathological response include the adaptive and innate immune systems, as well as the intestinal epithelium and endothelium. Advances in the understanding of the roles of each of these components have resulted in the development of multiple biological agents that all represent an alternative to the use of current therapies in patients with refractory Crohn's disease or ulcerative colitis. This study systematically reviews the mechanisms of action, efficacy and safety of new and emerging therapies that are currently in clinical trials and discusses future directions in the treatment of IBD.

  • Experimental colitis
  • IBD basic research
  • IBD clinical
  • inflammatory bowel disease
  • mucosal immunity

Statistics from Altmetric.com

Footnotes

  • Competing interests Silvio Danese has served as a speaker, a consultant and an advisory board member for Schering-Plough, Abbott Laboratories, UCB, Ferring, Cellerix, Millenium Takeda, Nycomed, Actelion, Astra Zeneca, Danone, Chiesi, Novo Nordisk, Merk-Serono and Cosmo Pharmaceuticals.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.